$RDHL News

$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma

RedHill Biopharma’s Partner University Of Oklahoma Receives $2.9M In Funding From National Cancer Institute To Study, In Clinical Trials, Whether RedHill's Opaganib, Given After CAR T-Cell Therapy, May Help Immune Cells Fight Cancer More Effectively

RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results

Redhill Biopharma H1 2026 EPS $0.00 And Revenue $0.00

RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

Redhill Biopharma Stock Doubles In One Session — Here's Why

RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

Redhill Biopharma Stock Doubles In One Session — Here's Why

Redhill Biopharma Divests Talicia Business To Apotex Health Subsidiary For An Upfront Payment Of $18M Plus Up To An Additional $35M In Potential Sales-based Milestone Payments

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

RedHill Biopharma Announces Up To $19.4 Million Private Placement

RedHill Biopharma Commences ~$6M Offering Of American Depositary Shares, Series A-2 Warrants At $0.70/ADS

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

RedHill Biopharma Engages WHO Solidarity Platform And Pharma Partners To Advance Opaganib As Oral Host Directed Therapy For Ebola Virus Disease Amid Bundibugyo Outbreak Showing Preclinical Filovirus Activity And Prior Phase 3 Antiviral Results

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

RedHill Biopharma Actively Discussing Potential Collaborations For Advancement Of Its Investigational Oral Drug, Opaganib, To Combat Ebola Virus Disease

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease